<DOC>
	<DOCNO>NCT02017327</DOCNO>
	<brief_summary>Primary objective : The primary objective demonstrate superiority Monoprost® versus Lumigan® 0.01 % Lumigan® 0.03 % Unit Dose term safety respect assessment conjunctival hyperaemia bad eye Day 84 . The conjunctival hyperaemia score use MacMonnies photographic scale ( 0 5 ) .</brief_summary>
	<brief_title>Safety Efficacy Assessment Monoprost® Comparison With Lumigan® 0.01 % Lumigan® 0.03 % Unit Dose</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<mesh_term>Bimatoprost</mesh_term>
	<criteria>Male female age ≥18 year old . Written informed consent . Association 3 follow criterion : 1 . Both eye primary open angle glaucoma ocular hypertension already treat control monotherapy Lumigan® 0.01 % since least 3 month ( accord European Glaucoma Society guideline ) . 2 . Intra Ocular Pressure ≤ 18 mm Hg eye . 3 . With local intolerance sign least one eye define association : 3.1 Hyperaemia = Grade ( 2 ) ( 3 ) ( 4 ) follow photographic MacMonnies scale . And 3.2.1 Presence least 2 symptom level severity ≥ 1 ( = mild moderate severe ) among follow 5 symptom : irritation/burning , itching , tear , eye dryness sensation , foreign body sensation . And/Or 3.2.2 Presence least 2 sign level severity ≥ 1 ( = mild moderate severe ) among follow 3 sign : superficial punctate keratitis , blepharitis , eyelid skin darkness . Presence least one severe objective sign among follow : Global ocular staining Oxford ( 015 ) grade scheme &gt; 12 . Blepharitis ( Grade 4 : Very severe , i.e . eczematiform lesion ) . Any ocular hypertension primary ocular hypertension primary chronic open angle glaucoma ( congenital , angle closure glaucoma , secondary glaucoma ) . Visual field perform available within 6 month inclusion visit . Fundus perform available within 6 month inclusion visit . Advanced stage glaucoma : Absolute defect ten degree central point visual field . Severe visual field loss accord investigator 's best judgement . Risk visual field worsen consequence participation trial accord investigator 's best judgement . Best far correct visual acuity ≤ 1/10 . History trauma , infection , inflammation within 3 month inclusion visit . Ongoing known history ocular allergy and/or uveitis and/or viral infection . Severe dry eye ( define severe epithelial erosion cornea and/or use dry eye medication frequency exceed 8 instillation / day ) . Corneal ulceration . Palpebral abnormality relate medical treatment study incompatible good evaluation . Any abnormality prevent accurate assessment e.g . reliable tonometry measurement , visual field examination . Systemic/non ophthalmic/ exclusion criterion Noncontrolled diabetic patient . Known suspected hypersensitivity one component study product . Any medical surgical history , disorder disease acute chronic severe organic disease : hepatic , endocrine , neoplastic , haematological ; immunosuppressive , infectious disease , severe psychiatric illness , relevant cardiovascular abnormality , etc… and/or complicate factor structural abnormality , judge investigator incompatible study . Specific exclusion criterion woman Pregnancy , lactation . Childbearing potential woman use reliable method contraception ( oral contraceptive , intrauterine device , subcutaneous contraceptive implant , vaginal ring , patch ) surgically sterilise .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>